Vanda Pharmaceuticals risk/reward favorable at current levels, says Caris
Caris finds the risk/reward on Vanda shares favorable with the company's launch of Fanapt approaching. The firm reiterates a Buy rating on the stock with a $20 price target. :theflyonthewall.com
News For VNDA From The Last 14 Days
Check below for free stories on VNDA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
